Show simple item record

Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation

dc.contributor.authorFanikos, John
dc.contributor.authorTsilimingras, Kanella
dc.contributor.authorKucher, Nils
dc.contributor.authorRosen, Allison B.
dc.contributor.authorHieblinger, Melissa D.
dc.contributor.authorGoldhaber, Samuel Z.
dc.date2022-08-11T08:10:44.000
dc.date.accessioned2022-08-23T17:18:03Z
dc.date.available2022-08-23T17:18:03Z
dc.date.issued2004-01-13
dc.date.submitted2011-01-14
dc.identifier.citationAm J Cardiol. 2004 Jan 15;93(2):247-50.
dc.identifier.issn0002-9149 (Linking)
dc.identifier.pmid14715362
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47770
dc.description.abstractWe compared the efficacy, safety, and impact on postoperative hospital length of stay and inpatient hospital costs of low-molecular-weight heparin with that of unfractionated heparin as a "bridge" to achieving therapeutic levels of anticoagulation with warfarin in patients with newly implanted prosthetic heart valves. The patients who received low-molecular-weight heparin had a shorter length of stay and decreased postoperative costs compared with the control subjects receiving unfractionated heparin.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=14715362&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.amjcard.2003.09.054
dc.subjectAnticoagulants
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subject*Heart Valve Prosthesis Implantation
dc.subjectHeparin
dc.subjectHeparin, Low-Molecular-Weight
dc.subjectHospital Costs
dc.subjectHumans
dc.subjectInfusions, Intravenous
dc.subjectLength of Stay
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectSafety
dc.subjectWarfarin
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titleComparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation
dc.typeJournal Article
dc.source.journaltitleThe American journal of cardiology
dc.source.volume93
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/889
dc.identifier.contextkey1729421
html.description.abstract<p>We compared the efficacy, safety, and impact on postoperative hospital length of stay and inpatient hospital costs of low-molecular-weight heparin with that of unfractionated heparin as a "bridge" to achieving therapeutic levels of anticoagulation with warfarin in patients with newly implanted prosthetic heart valves. The patients who received low-molecular-weight heparin had a shorter length of stay and decreased postoperative costs compared with the control subjects receiving unfractionated heparin.</p>
dc.identifier.submissionpathqhs_pp/889
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages247-50


This item appears in the following Collection(s)

Show simple item record